January 2020

FDA approves Dextenza for treatment of postoperative ocular pain

Dextenza (dexamethasone ophthalmic insert 0.4 mg) is the first FDA-approved intracanalicular insert to deliver dexamethasone to treat postoperative ocular pain for up to 30 days with one treatment. Dextenza demonstrated efficacy in two randomized, vehicle-controlled phase 3 studies. A statistically significant number of patients who received Dextenza were free of pain 8 days after cataract surgery compared with patients in the vehicle control group. In addition, safety was demonstrated in… Read More »FDA approves Dextenza for treatment of postoperative ocular pain

FDA APPROVES BAK FREE LATANOPROST FOR BETTER RESULTS

Latanoprost, is a medication utilized to deal with boosted pressure inside the eye. This consists of eye high blood pressure as well as open angle glaucoma. It is applied as eye drops (topical treatment) to the eyes. Start of effects is typically within 4 hours, and also, they last for as much as a day. Latanoprost was authorized for medical usage in the USA in 1996. It is on the… Read More »FDA APPROVES BAK FREE LATANOPROST FOR BETTER RESULTS

The FDA has approved Oxervate for treatment of neurotrophic keratitis

DompĂ© receives FDA approval cenegermin eye drops, first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis cenegermin is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology. The first treatment specifically indicated for neurotrophic keratitis (NK), cenegermin has a mechanism of action that targets the root pathology of the disease. cenegermin… Read More »The FDA has approved Oxervate for treatment of neurotrophic keratitis